drugset
drugset / Trial / NCT05404542

To Evaluate Pharmacokinetics (PK) and Safety of Tavapadon in Participants With Severe Renal Impairment Compared to Participants With Normal Renal Function

NCT05404542 ↗

Phase 1 Completed 14 enrolled Cerevel Therapeutics, LLC
Non-randomizedParallel-groupOpen-labelTreatment

Summary

The primary purpose is to assess the effect of renal impairment on the PK of tavapadon following administration of a single oral dose in participants with severe renal impairment relative to age, body weight, and sex-matched participants with normal renal function.

Timeline

Start
2022-05-10
Primary completion
2023-08-14
Completion
2023-08-14

Drugs

EvaluationDrugModalityDoseRoute
Subject Tavapadon Small molecule 0.25 mg Oral

Indications

impaired renal function disease